{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:23:16Z","timestamp":1740144196903,"version":"3.37.3"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"43","license":[{"start":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T00:00:00Z","timestamp":1603411200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Currently, the 5-year survival rate remains poor for patients with metastatic colorectal cancer (mCRC), and the purpose of therapy is to prolong survival while maintaining the quality of life. Trifluridine\/tipiracil, an oral drug combining trifluorothymidine and a thymidine phosphorylase inhibitor, is indicated as salvage therapy for mCRC patients who have progressed after all available regimens. Combination of local treatments with systemic therapy such as trifluridine\/tipiracil represents an apt management strategy for mCRC patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 72-year-old man diagnosed with stage IV rectal adenocarcinoma (KRAS mutation) with peritoneal carcinomatosis and liver metastases developed resistance to 2 lines of treatment (bevacizumab\/irinotecan\/S-1 and bevacizumab\/oxaliplatin\/HDFL [high-dose 24-hour infusion of 5-fluorouracil and leucovorin regimen]) within 5 months.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>Refractory stage IV rectal adenocarcinoma.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>Systemic treatment of trifluridine\/tipiracil has been given for approximately 15 months in addition to radiotherapy, Yttrium-90 radioembolization, and trans-arterial chemoembolization for peritoneal and liver metastases.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>After 15 months, the patient was still taking trifluridine\/tipiracil for disease control with a good quality of life.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>Trifluridine\/tipiracil plus other appropriate local therapy may significantly prolong patients survival with a satisfactory quality of life for patients with refractory mCRC. The favorable safety profile of trifluridine\/tipiracil renders it a suitable option to be combined with other local therapies for metastatic lesions.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000022780","type":"journal-article","created":{"date-parts":[[2020,10,24]],"date-time":"2020-10-24T01:04:14Z","timestamp":1603501454000},"page":"e22780","source":"Crossref","is-referenced-by-count":5,"title":["Trifluridine\/tipiracil in combination with local therapy may be a favorable option for refractory metastatic colorectal cancer patients"],"prefix":"10.1097","volume":"99","author":[{"given":"Yu-Lin","family":"Lin","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Cardinal Tien Hospital, New Taipei City"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kao-Lang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Medical Imaging, National Taiwan University Cancer Center, National Taiwan University Hospital and National Taiwan University College of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8354-1758","authenticated-orcid":false,"given":"Been-Ren","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Surgery, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,10,23]]},"reference":[{"key":"R1-20230916","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ejca.2018.07.005","article-title":"Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018","volume":"103","author":"Ferlay","year":"2018","journal-title":"European J Cancer"},{"key":"R2-20230916","first-page":"105","article-title":"Epidemiology of colorectal cancer","volume":"7","author":"Marley","year":"2016","journal-title":"Int J Mol Epidemiol Genet"},{"key":"R3-20230916","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3322\/caac.21395","article-title":"Colorectal cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"R7-20230916","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet (London, England)"},{"key":"R8-20230916","first-page":"381","article-title":"Thymidine kinase and thymidine phosphorylase level as the main predictive parameter for sensitivity to TAS-102 in a mouse model","volume":"11","author":"Emura","year":"2004","journal-title":"Oncol Rep"},{"key":"R9-20230916","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0006-2952(00)00253-7","article-title":"Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2\u2019-deoxyribonucleosides","volume":"59","author":"Fukushima","year":"2000","journal-title":"Biochem Pharmacol"},{"key":"R10-20230916","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N Engl J Med"},{"key":"R11-20230916","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1200\/JCO.2017.74.3245","article-title":"Results of a randomized, double-blind, placebo-controlled, phase iii trial of trifluridine\/tipiracil (tas-102) monotherapy in Asian patients with previously treated metastatic colorectal cancer: the terra study","volume":"36","author":"Xu","year":"2018","journal-title":"J Clin Oncol"},{"key":"R12-20230916","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet (London, England)"},{"key":"R13-20230916","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.clcc.2017.10.016","article-title":"A comparison of regorafenib and TAS-102 for metastatic colorectal cancer: a systematic review and network meta-analysis","volume":"17","author":"Abrahao","year":"2018","journal-title":"Clin Colorectal Cancer"},{"key":"R14-20230916","first-page":"4299","article-title":"Efficacy and safety of regorafenib or TAS-102 in patients with metastatic colorectal cancer refractory to standard therapies","volume":"36","author":"Sueda","year":"2016","journal-title":"Anticancer Res"},{"key":"R15-20230916","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1080\/14740338.2018.1475557","article-title":"The safety of trifluridine and tipiracil for the treatment of metastatic colorectal cancer","volume":"17","author":"Martinez-Perez","year":"2018","journal-title":"Expert Opin Drug Saf"},{"key":"R16-20230916","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ctrv.2017.04.007","article-title":"Treatment decisions in metastatic colorectal cancer - Beyond first and second line combination therapies","volume":"59","author":"Vogel","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"R17-20230916","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","article-title":"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial","volume":"15","author":"Heinemann","year":"2014","journal-title":"Lancet Oncol"},{"issue":"(15_suppl)","key":"R18-20230916","doi-asserted-by":"crossref","first-page":"LBA3","DOI":"10.1200\/jco.2014.32.18_suppl.lba3","article-title":"CALGB\/SWOG 80405: Phase III trial of irinotecan\/5-FU\/leucovorin (FOLFIRI) or oxaliplatin\/5-FU\/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC)","volume":"32","author":"Venook","year":"2014","journal-title":"J Clin Oncol"},{"key":"R19-20230916","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1093\/annonc\/mdr571","article-title":"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306","volume":"23","author":"Stintzing","year":"2012","journal-title":"Ann Oncol"},{"key":"R20-20230916","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ejca.2017.03.023","article-title":"Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study","volume":"79","author":"Stintzing","year":"2017","journal-title":"European J Cancer (Oxford, England: 1990)"},{"key":"R21-20230916","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.clcc.2019.04.003","article-title":"Regorafenib Is associated with increased skeletal muscle loss compared to TAS-102 in metastatic colorectal cancer","volume":"18","author":"Huemer","year":"2019","journal-title":"Clin Colorectal Cancer"},{"key":"R22-20230916","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1186\/s12885-016-2491-y","article-title":"Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study","volume":"16","author":"Kasi","year":"2016","journal-title":"BMC Cancer"},{"key":"R23-20230916","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.21873\/anticanres.13551","article-title":"The Onset of Grade >\/=3 neutropenia is associated with longer overall survival in metastatic colorectal cancer patients treated with trifluridine\/tipiracil","volume":"39","author":"Giuliani","year":"2019","journal-title":"Anticancer Res"},{"key":"R24-20230916","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.clcc.2016.07.005","article-title":"Neutropenia as a predictive factor in metastatic colorectal cancer treated with TAS-102","volume":"16","author":"Hamauchi","year":"2017","journal-title":"Clin Colorectal Cancer"},{"key":"R25-20230916","doi-asserted-by":"crossref","first-page":"e531","DOI":"10.1016\/j.clcc.2018.04.002","article-title":"Real-world treatment patterns among patients with colorectal cancer treated with trifluridine\/tipiracil and regorafenib","volume":"17","author":"Patel","year":"2018","journal-title":"Clin Colorectal Cancer"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000022780","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T03:48:05Z","timestamp":1694836085000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000022780"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2020,10,23]]},"references-count":22,"journal-issue":{"issue":"43","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000022780","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2020,10,23]]}}}